In thyroid cancer, Severson et al. showed that gal-9 is expressed by tumor-infiltrating lymph nodes, and thus may contribute to immune dysfunction, suggesting that immune-modulating therapies that inhibit TIM-3/gal-9 may be viable options for patients with advanced diseases [86]. The gene discussed is LGALS9; the disease is neoplasm.